Add news
March 2010
April 2010
May 2010June 2010July 2010
August 2010
September 2010October 2010
November 2010
December 2010
January 2011
February 2011March 2011April 2011May 2011June 2011July 2011August 2011September 2011October 2011November 2011December 2011January 2012February 2012March 2012April 2012May 2012June 2012July 2012August 2012September 2012October 2012November 2012December 2012January 2013February 2013March 2013April 2013May 2013June 2013July 2013August 2013September 2013October 2013November 2013December 2013January 2014February 2014March 2014April 2014May 2014June 2014July 2014August 2014September 2014October 2014November 2014December 2014January 2015February 2015March 2015April 2015May 2015June 2015July 2015August 2015September 2015October 2015November 2015December 2015January 2016February 2016March 2016April 2016May 2016June 2016July 2016August 2016September 2016October 2016November 2016December 2016January 2017February 2017March 2017April 2017May 2017June 2017July 2017August 2017September 2017October 2017November 2017December 2017January 2018February 2018March 2018April 2018May 2018June 2018July 2018August 2018September 2018October 2018November 2018December 2018January 2019February 2019March 2019April 2019May 2019June 2019July 2019August 2019September 2019October 2019November 2019December 2019January 2020February 2020March 2020April 2020May 2020June 2020July 2020August 2020September 2020October 2020November 2020
News Every Day |

Poorer Countries May Have to Wait Years for a COVID Vaccine

Poorer Countries May Have to Wait Years for a COVID Vaccine
Protesters advocating for price controls on COVID-19 vaccines outside Moderna Therapeutics headquarters

A COVID-19 vaccine appears to be on the way, raising plenty of questions about how much vaccines will cost and who get will get them first.

On Monday, Moderna announced initial results from a clinical trial showing that its COVID-19 vaccine is 94.5 percent effective. That’s promising news for people in the United States, where COVID-19 is surging and the government invested heavily in developing the vaccine.

However, consumer advocates warn U.S. taxpayers will ultimately pay twice for Moderna’s vaccine if it’s approved by regulators. A $2.5 billion public investment by the Trump administration covers the cost of bringing the vaccine to market — and pays for the vaccine itself. This gives Americans quick access to the vaccine once it is approved in the U.S., but much of the world could be left behind during a pandemic that knows no borders.

Disparities in global vaccine sales and distribution exacerbated by propriety control of manufacturing technologies are expected to create a “global vaccine apartheid,” in which wealthy countries distribute COVID-19 vaccines within their borders for months, if not years, before poorer nations have access, according to Peter Maybarduk, director of the Access to Medicines program at Public Citizen.

“If we fail to act, potentially billions of people around the world will experience a longer pandemic, and that, of course, will mean many deaths, but also economic devastation for vulnerable communities, as well as potential political instability,” Maybarduk said in an interview.

As Truthout has reported, private pharmaceutical companies have neglected vaccine research for decades because other medicines are more profitable, leaving the job up to governments and public research institutions. Since the COVID-19 pandemic hit, Moderna and other companies racing to develop vaccines have received billions of dollars in development aid from wealthy governments and international foundations working with the World Health Organization (WHO).

Maybarduk said these funders are responsible to the public, not a pharmaceutical company’s profit margins, and they should leverage their stake in any future vaccines to make them affordable and widely available on a global scale.

“In the worst health crisis in a century, vaccine funders must use every tool at their disposal to share technology and teach the world to make vaccines,” Maybarduk said. “Governments and foundations must learn to use their power and tell pharmaceutical corporations what to do if we are to prevent a global vaccine apartheid.”

The U.S. enjoys a significant stake in leading vaccines thanks to publicly funded research and development shared with private industry. Along with Pfizer, which announced preliminary but promising results from its vaccine trial last week, Moderna relied on technology developed by the National Institutes of Health (NIH) — and paid for by taxpayers — that stabilizes coronavirus “spike” proteins for research. Johnson & Johnson, Novavax and other companies in the race to develop a vaccine are also using the technology, according to Public Citizen.

Moderna’s vaccine quest also benefited from nearly $1 billion in federal research and development aid, which covers 100 percent of the cost of bringing the vaccine to the Food and Drug Administration for approval. Even after that investment, the Trump administration agreed to pay an additional $1.5 billion for 100 million doses of the vaccine. The U.S. has the option of buying another 500 million doses, which translates to $8 billion in profits for Moderna.

“This is the people’s vaccine. The NIH’s vaccine. It is not merely Moderna’s vaccine,” Maybarduk said. “Federal scientists helped invent it and taxpayers are funding its development. We all have played a role. It should belong to humanity.”

President Trump believed approving a vaccine ahead of the election would benefit his reelection chances, and he repeatedly lied to voters about when a vaccine would be available while attempting to take credit for development efforts. The Trump administration redirected billions of federal dollars earmarked for personal protective equipment and public health agencies battling the pandemic to fund a partnership between the government and private vaccine developers.

The Trump administration clearly took an “America First” approach to vaccine development. Unless people in all countries have access to vaccines, the global pandemic could drag on for years. Even in the unlikely event that the five leading vaccines are approved, two-thirds of the world’s population will not have access until at least 2022, according to Oxfam International.

Moderna says it can produce 1 billion doses of its vaccine by the end of next year, but 78 percent of those doses have already been sold to the U.S. and wealthy nations in Europe representing only 12 percent of the world’s population, according to Global Justice Now, an international group aligned with social movements.

However, Moderna was one of several beneficiaries of a $1.1 billion investment by the Coalition for Epidemic Preparedness Innovations (CEPI), which co-leads the WHO’s COVID-19 vaccine access facility with support from the World Bank and wealthy foundations.

In a new report, Public Citizen argues that Moderna appears to be violating CEPI’s “equitable access policy” that prioritizes vaccine access by public health need, instead of the ability to pay, by securing purchase agreements with only the U.S. and other wealthy nations.

“We welcome any good news when it comes to a coronavirus breakthrough, but sadly most of the world cannot celebrate today,” said Global Justice Now Director Nick Dearden, in a statement. “Moderna’s is predicted to be the most expensive potential vaccine on the market, at around $35 a dose, even though it has been made with vast public support.”

While those prices may be lower in the U.S., taxpayers have already invested millions into Moderna’s vaccine, and Moderna plans on turning a profit, according to Public Citizen. President-Elect Joe Biden has said a vaccine will be available to everyone in the U.S. “free of charge,” but Trump’s refusal to accept the election results and allow for a transition between his administration and Biden’s could hinder a vaccine rollout. In any case, a vaccine would first be distributed to health workers and vulnerable patients before the public at large.

Maybarduk said both administrations should engage with CEPI and use the U.S.’s stake in vaccine development to ramp up global production and distribution. Human rights groups say Moderna and other leading vaccine developers must share technology and insight for manufacturing any vaccines that come to market with the world. No single corporation has the capability of distributing a vaccine globally, and many countries will need knowledge and technology currently held by private companies that received public support.

“The U.S. government has tremendous power to do this and frankly save the world, we’re talking about that level of thing,” Maybarduk said.

While Moderna has pledged not to enforce its vaccine patents during the pandemic, potentially allowing governments and drug makers to replicate its vaccine production methods, it remains unclear how Moderna will define the “end” of the pandemic.

Stephen Cockburn, the head of economic and social justice programs at Amnesty International, said Moderna and other profit-seeking vaccine makers must be held accountable to global public health needs during this unprecedented crisis.

“Having already sold most of its potential 2021 vaccine supply to rich countries, Moderna must follow through on its promise to allow others to make the vaccine, and provide the knowledge and technology to do so, once the vaccine has proven to be safe and effective,” Cockburn said in a statement on Monday.




Read also

Teachers union’s latest bid to bury any hope for NYC schoolchildren

Will America Build a Monument to Commemorate Coronavirus?

BBC star Clare Balding refuses to cover men’s football over ‘vile abuse’ on ‘toxic’ social media



News, articles, comments, with a minute-by-minute update, now on Today24.pro




Today24.pro — latest news 24/7. You can add your news instantly now — here